The relationship between inflammation markers, positron emission tomography/ /computed tomography parameters and disease prognosis in advanced non-small-cell lung cancer patients

被引:0
|
作者
Pirincci, Esra [1 ]
Oruc, Zeynep [2 ]
Ebinc, Senar [3 ,6 ]
Guzel, Yunus [4 ]
Komek, Halil [4 ]
Kucukoner, Mehmet [5 ]
Urakci, Zuhat [2 ]
Kaplan, Muhammet Ali [2 ]
Tasdemir, Bekir [5 ]
Isikdogan, Abdurrahman
机构
[1] Dicle Univ, Fac Med, Dept Hematol, Diyarbakir, Turkiye
[2] Dicle Univ, Fac Med, Dept Med Oncol, Diyarbakir, Turkiye
[3] Gazi Yasargil Training & Res Hosp, Dept Med Oncol, Diyarbakir, Turkiye
[4] Gazi Yasargil Training & Res Hosp, Dept Nucl Med, Diyarbakir, Turkiye
[5] Dicle Univ, Fac Med, Dept Nucl Med, Diyarbakir, Turkiye
[6] Gazi Yasargil Training & Res Hosp, Dept Med Oncol, Billst Sur, TR-21280 Diyarbakir, Turkiye
来源
ONCOLOGY IN CLINICAL PRACTICE | 2024年 / 20卷 / 04期
关键词
inflammation; non-small-cell lung cancer; PET/CT; LYMPHOCYTE RATIO; NEUTROPHIL; MUTATIONS; SURVIVAL; OUTCOMES; PET/CT;
D O I
10.5603/ocp.97451
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Introduction. Inflammation is known to be related to the development, spread, prognosis, and treatment response in cancer patients. Our study aimed to evaluate the correlation between inflammation indices and positron emission tomography-computed tomography (PET/CT) parameters and investigate their relationship with progression-free survival (PFS) and overall survival (OS) in patients diagnosed with stage-IV non -small cell lung cancer (NSCLC). Material and methods. Demographic, clinicopathological, laboratory, and PET/CT data of 179 patients diagnosed with stage-IV NSCLC who presented to the Oncology Department of Dicle University, Faculty of Medicine between 2010-2020 were retrieved from patient files and the hospital database system. Results. The median age at diagnosis was 64 (27-87) years. All patients included in the study had NSCLC: 72.6% had adenocarcinoma, 21.2% had squamous cell carcinoma, and 6.1% had other histological types. Of the 78 patients who were subjected to molecular analysis, 26 (33.3%) were EGFR-mutation positive. During the 10-month median follow-up, median first -line PFS was 6 months (95% CI 5.00-6.99), and median OS was 10 months (95% CI 7.8-12.1). The multivariate analysis performed for first -line PFS determined hemoglobin (HR = 1.01; 95% CI 1.003-1.02; p = 0.005) and PET total lesion glycolysis (TLG) (HR = 1.002; 95% CI 1.001-1.003; p = 0.003) values as independent prognostic factors. The multivariate analysis for OS determined positive EGFR mutation status (HR = 0.385; 95% CI 0.213-0.696; p = 0,014) and performance status (HR = 1.88; 95% CI 1.092-3.238; p = 0,008) as independent prognostic factors. Conclusions. Our study determined the hemoglobin level and PET TLG from PET/CT parameters to be independent prognostic factors for PFS, and performance status and EGFR mutation positivity to be independent prognostic factors for OS.
引用
收藏
页数:10
相关论文
共 50 条
  • [21] Is there a role for positron emission tomography/computed tomography in the staging of small-cell lung cancer?
    Truong, Mylene T.
    Marom, Edith M.
    CLINICAL LUNG CANCER, 2008, 9 (01) : 8 - 8
  • [22] Intrathoracic patterns of failure for non-small-cell lung cancer with positron-emission tomography/computed tomography-defined target delineation
    Klopp, Ann Hoge
    Chang, Joe Y.
    Tucker, Susan L.
    Sulman, Erik P.
    Balter, Peter A.
    HelenLiu, H.
    Bucci, M. Kara
    Macapinlac, Homer A.
    Komaki, Ritsuko
    Cox, James D.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2007, 69 (05): : 1409 - 1416
  • [23] Does computed tomography or positron emission tomography response after neoadjuvant chemotherapy for resectable non-small-cell lung cancer predict survival?
    Patz, Edward F., Jr.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (28) : 4542 - 4543
  • [24] Positron emission tomography is superior to computed tomography scanning for response-assessment after radical radiotherapy or chemoradiotherapy in patients with non-small-cell lung cancer
    Mac Manus, MP
    Hicks, RJ
    Matthews, JP
    McKenzie, A
    Rischin, D
    Salminen, EK
    Ball, DL
    JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (07) : 1285 - 1292
  • [25] Efficacy of 18F-fluorodeoxyglucose positron emission tomography/computed tomography as a predictor of response in locally advanced non-small-cell carcinoma of the lung
    Roy, Soumyajit
    Pathy, Sushmita
    Kumar, Rakesh
    Mohanti, Bidhu K.
    Raina, Vinod
    Jaiswal, Anand
    Taywade, Sameer
    Garg, Kavita
    Thulkar, Sanjay
    Mohan, Anant
    Mathur, Sandeep
    Behera, Digamber
    NUCLEAR MEDICINE COMMUNICATIONS, 2016, 37 (02) : 129 - 138
  • [26] Preoperative staging of non-small-cell lung cancer with positron-emission tomography.
    Pieterman, RM
    van Putten, JWG
    Meuzelaar, JJ
    Mooyaart, EL
    Vaalburg, W
    Koëter, GH
    Fidler, V
    Pruim, J
    Groen, HJM
    NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (04): : 254 - 261
  • [27] Mediastinal staging in non-small-cell lung carcinoma: computed tomography versus F-18-fluorodeoxyglucose positron-emission tomography and computed tomography
    Stefan Walbom Harders
    Hans Henrik Madsen
    Karin Hjorthaug
    Anne Kirstine Arveschoug
    Torben Riis Rasmussen
    Peter Meldgaard
    Johanne Andersen Hoejbjerg
    Hans Kristian Pilegaard
    Henrik Hager
    Michael Rehling
    Finn Rasmussen
    Cancer Imaging, 14
  • [28] How useful is positron emission tomography for lymphnode staging in non-small-cell lung cancer?
    Liewald, F
    Grosse, S
    Storck, M
    Guhlmann, A
    Halter, G
    Reske, S
    Sunder-Plassmann, L
    THORACIC AND CARDIOVASCULAR SURGEON, 2000, 48 (02): : 93 - 96
  • [29] Positron emission tomography in assessing response to neoadjuvant chemotherapy for non-small-cell lung cancer
    Thomas, DM
    Mitchell, PLR
    Berlangieri, SU
    Tochon-Danguy, H
    Knight, S
    Clarke, CP
    Scott, AM
    MEDICAL JOURNAL OF AUSTRALIA, 1998, 169 (04) : 227 - 227
  • [30] Positron emission tomography in assessing response to neoadjuvant chemotherapy for non-small-cell lung cancer
    O'Donnell, GJ
    MEDICAL JOURNAL OF AUSTRALIA, 1999, 170 (05) : 236 - 237